Detailed Report on Mitogen Activated Protein Kinase 3MAP Kinase 3 -Pipeline Review, H1 2016

Mitogen Activated Protein Kinase 3MAP Kinase 3 or Insulin-Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or ERK-1 or EC 2.7.11.24-Pipeline Review, H1 2016 ​is a new market research publication announced by Reportstack. This report provides in depth analysis on Mitogen Activated Protein Kinase 3 (MAP Kinase 3 or Insulin-Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or ERK-1 or EC 2.7.11.24) targeted pipeline therapeutics.

The report provides comprehensive information on the Mitogen Activated Protein Kinase 3 (MAP Kinase 3 or Insulin-Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or ERK-1 or EC 2.7.11.24), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Mitogen Activated Protein Kinase 3 (MAP Kinase 3 or Insulin-Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or ERK-1 or EC 2.7.11.24) targeted therapeutics development and features dormant and discontinued projects.

Complete report available @ Mitogen Activated Protein Kinase 3MAP Kinase 3 or Insulin-Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or ERK-1 or EC 2.7.11.24-Pipeline Review, H1 2016

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape for Mitogen Activated Protein Kinase 3 (MAP Kinase 3 or Insulin-Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or ERK-1 or EC 2.7.11.24)
- The report reviews Mitogen Activated Protein Kinase 3 (MAP Kinase 3 or Insulin-Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or ERK-1 or EC 2.7.11.24) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report reviews latest news and deals related to Mitogen Activated Protein Kinase 3 (MAP Kinase 3 or Insulin-Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or ERK-1 or EC 2.7.11.24) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Mitogen Activated Protein Kinase 3 (MAP Kinase 3 or Insulin-Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or ERK-1 or EC 2.7.11.24) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies Mentioned

AGV Discovery, SAS Genentech, Inc. Kura Oncology, Inc. Laurent Pharmaceuticals Inc. Merck & Co., Inc. Merck KGaA

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###